With normal liver function tests, serum iron 296 µg/dL, transferrin saturation 71 %, and total iron‑binding capacity 414 µg/dL, what is the likely diagnosis and recommended management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Hereditary Hemochromatosis (HFE-Related)

With a transferrin saturation of 71% and normal liver function tests, you are dealing with hereditary hemochromatosis until proven otherwise, and the patient requires immediate HFE genetic testing followed by therapeutic phlebotomy if C282Y homozygosity is confirmed.

Diagnostic Interpretation

Your patient's iron studies are highly suggestive of iron overload:

  • Transferrin saturation of 71% is markedly elevated (normal <45% in men, <40% in women) 1
  • Serum iron of 296 µg/dL is significantly elevated (normal 60-80 µg/dL) 1
  • These values fall within the typical range for symptomatic hemochromatosis patients (TS 80-100%, serum iron 180-300 µg/dL) 1

The elevated transferrin saturation is the critical finding here—it indicates disturbed plasma iron homeostasis and inappropriately low hepcidin concentration, which is characteristic of hemochromatosis 2. A transferrin saturation >45% should trigger HFE mutation analysis 1.

Immediate Next Steps

1. HFE Genetic Testing (First Priority)

Order HFE mutation analysis to test for:

  • C282Y homozygosity (most common cause)
  • C282Y/H63D compound heterozygosity
  • Other HFE variants 1

2. Serum Ferritin Level (Critical Missing Data)

You need the ferritin level urgently, as it:

  • Correlates with total body iron stores 1
  • Predicts risk of cirrhosis (ferritin >1000 µg/L with elevated transaminases predicts cirrhosis in 80% of C282Y homozygotes) 1
  • Determines whether liver biopsy is needed 1

Risk Stratification Based on Ferritin

Once you obtain the ferritin level:

If ferritin <1000 µg/L:

  • Cirrhosis is unlikely 1
  • Proceed directly to therapeutic phlebotomy if C282Y homozygous 1
  • No liver biopsy needed 1

If ferritin >1000 µg/L:

  • High risk for advanced fibrosis/cirrhosis 1
  • Check liver enzymes (ALT/AST) and platelet count
  • If ALT/AST elevated AND platelets <200, cirrhosis present in 80% 1
  • Consider liver MRI (R2* sequence) to quantify hepatic iron concentration 2
  • May need liver biopsy to assess fibrosis stage 1

Management Algorithm

For C282Y Homozygotes (Most Likely Scenario):

Induction Phase:

  • Phlebotomy 1-2 times weekly (500 mL removes 200-250 mg iron) 1
  • Check hemoglobin/hematocrit before each session—don't drop below 80% of baseline 1
  • Monitor ferritin every 10-12 phlebotomies (approximately every 3 months) 1
  • Target: Ferritin <50 µg/L 3

Maintenance Phase:

  • Once ferritin reaches 50-100 µg/L, switch to maintenance 1
  • Target: Ferritin <100 µg/L 3
  • Frequency varies (monthly to 1-2 units/year depending on reaccumulation rate) 1

Additional Monitoring Considerations:

The transferrin saturation of 71% is concerning because TSAT >75% suggests harmful non-transferrin-bound iron (NTBI) levels that drive tissue damage 4. While current guidelines focus primarily on ferritin targets, emerging evidence suggests monitoring TSAT during maintenance therapy may improve outcomes, as high TSAT correlates with symptoms like fatigue and joint pain 4.

Assessment for Complications

Given the markedly elevated transferrin saturation, evaluate for end-organ damage:

  • Liver: Already have normal LFTs (good sign), but assess for fibrosis if ferritin >1000 µg/L
  • Cardiac: Screen for cardiomyopathy/arrhythmias if symptomatic (cardiac MRI if indicated) 2
  • Endocrine: Check glucose, testosterone, thyroid function 1
  • Joints: Assess for arthropathy (though phlebotomy doesn't reverse this) 1

Critical Pitfalls to Avoid

  1. Don't delay phlebotomy waiting for genetic results if ferritin is very high and patient is symptomatic—treatment is safe and prevents irreversible organ damage 1

  2. Don't create iron deficiency—stop when ferritin reaches 50-100 µg/L, not zero 1

  3. If ferritin >1000 µg/L with cardiac involvement, avoid rapid iron mobilization—risk of sudden death from toxic low-molecular-weight iron chelates 1

  4. Don't assume elevated ferritin alone means iron overload—ferritin is an acute phase reactant. The elevated transferrin saturation (71%) is what makes this iron overload, not inflammation 2, 5

Family Screening

Once diagnosis confirmed, screen all first-degree relatives with simultaneous HFE genotyping and iron studies (ferritin + transferrin saturation) 1.

Prognosis

If treated before cirrhosis and diabetes develop, survival is normal 1. The normal liver function tests are encouraging, but you must determine the ferritin level and fibrosis stage to fully assess prognosis.

References

3
Research

[Recommendations of EASL clinical practice guidelines on haemochromatosis].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2022

Related Questions

What do a normal total serum iron, normal total iron‑binding capacity, high‑normal transferrin saturation, and markedly elevated ferritin indicate, and how should this be treated?
What does a transferrin saturation of 26.6% with a ferritin level of 260 ng/mL indicate, and what further evaluation is recommended?
In a perimenopausal woman with hereditary hemochromatosis who has low serum iron, low transferrin, low total iron‑binding capacity, high transferrin saturation, and low‑normal ferritin, is any iron‑reducing treatment required?
What is the likely diagnosis and recommended management for a patient with transferrin saturation of 56%, serum iron of 180 µg/dL, and normal total iron‑binding capacity and ferritin?
What is the differential diagnosis and recommended management for a patient with high serum iron, high transferrin saturation, and low ferritin?
In a patient with anxiety treated with Adderall (amphetamine/dextroamphetamine) and sertraline, who develops new bruising, which medication should be adjusted?
Can a patient with a breast infection and active drainage, whose skin culture grew only normal skin flora, continue the current antibiotic therapy?
What are the uses, effects, and contraindications of daily oral N‑acetylcysteine supplementation in a 40‑ to 50‑year‑old male mechanic with heavy nicotine dependence, recent cessation of chronic alcohol use (previously 3–8 drinks daily) and daily heavy energy‑drink consumption, who experiences chronic brain fog and post‑prandial malaise?
In a 75-year-old patient with primary myelofibrosis JAK2‑positive receiving low-dose ruxolitinib (10 mg twice daily) for anemia, a follow-up bone‑marrow biopsy shows a hypocellular, dysplastic marrow suggestive of drug‑induced aplasia/hypoplasia; what is the appropriate management?
What is Displastin and is it an FDA‑approved treatment for cervical dysplasia?
What venous thromboembolism prophylaxis anticoagulant is appropriate for an elderly, bedridden patient with a hip fracture receiving chronic hemodialysis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.